^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | TTI-101 oral (STAT3 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
FDA Grants Fast Track Designation to Tvardi Therapeutics’ TTI-101 for Hepatocellular Carcinoma
Published date:
10/19/2022
Excerpt:
Tvardi Therapeutics, Inc...announced that its lead product, TTI-101, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed/refractory locally advanced, unresectable, or metastatic hepatocellular carcinoma (HCC).
